Fri, Feb 27, 2015, 1:46 AM EST - U.S. Markets open in 7 hrs 44 mins

Recent

% | $
Quotes you view appear here for quick access.

Dendreon Corporation Message Board

  • dinepat203 dinepat203 Jun 18, 2013 11:24 AM Flag

    Does Provenge Work Better with Xtandi?

    Does Provenge Work Better with Xtandi read this article on May 18, 2013 by Pat F. Bass III, M.D., M.S., M.P.H.

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • Yes, it was proven that Provenge works either concurrently, or sequentially with ADT treatments such as Xtandi or Zytiga.

    • Send to:

      Urology. 2013 Feb;81(2):381-3. doi: 10.1016/j.urology.2012.10.044.

      Complete biochemical (prostate-specific antigen) response to sipuleucel-T with enzalutamide in castration-resistant prostate cancer: a case report with implications for future research.

      Graff JN, Drake CG, Beer TM.

      Source

      Portland Veterans Affairs Medical Center, Portland, OR 97239, USA. graffj@ohsu.edu

      Abstract

      OBJECTIVE:

      To describe the case of a patient with castration-resistant, metastatic prostate cancer who achieved a complete and durable biochemical response after treatment with sipuleucel-T while continuing with enzalutamide and to explore the immunologic basis for such a response.

      MATERIALS AND METHODS:

      We obtained serial prostate-specific antigen (PSA) measurements and bone scans to assess the patient's response to enzalutamide followed by the addition of sipuleucel-T. Using preclinical and clinical data, we describe his response through known immunobiologic mechanisms.

      RESULTS:

      This patient's PSA level became undetectable during treatment with enzalutamide and began to increase again after 14 months. He opted for treatment with sipuleucel-T, while continuing with the enzalutamide. This resulted in another complete PSA response 6 months after exposure to sipuleucel-T.

      CONCLUSION:

      Sipuleucel-T typically does not produce significant PSA reductions, and, to the best of our knowledge, only 1 previous report of a durable complete PSA response in a patient with metastatic disease has been published. The timing of this response supports an immune mechanism. The biologic rationale for the combination, coupled with the clinical result observed in our patient, provides a basis for studies of the combination of sipuleucel-T and enzalutamide.

      Published by Elsevier Inc.

      PMID: 23374810 [PubMed - indexed for MEDLINE]

 
DNDN
0.1270.000(0.00%)Nov 18 4:00 PMEST

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.